Introduction
============

Inositol phospholipids are important regulators of cell physiology, and their head group interactions play fundamental roles in controlling membrane--cytosol interfaces. In addition to affecting signal transduction at the cell surface, these lipids regulate membrane traffic, nuclear events, the permeability and transport functions of membranes, and the cytoskeleton ([@bib10]). Phosphatidylinositol 4,5-bisphosphate (PIP~2~) plays roles in the recruitment and activation of a wide variety of actin regulatory proteins at the plasma membrane in order to regulate the release of cytokines, and to affect cell shape and motility, as well as several other processes ([@bib36], [@bib37]; [@bib40]; [@bib68]). Binding of PIP~2~ is also critical for the function of actin-binding proteins that serve to link cell--cell or cell--matrix adhesion complexes at the plasma membrane with the actin cytoskeleton. There currently is a major conceptual gap in our understanding of how PIP~2~ binds to and alters the function of these adaptor/scaffold proteins, such as vinculin, at the molecular level.

Vinculin functions as a central regulator of adherens junctions (AJs) and focal adhesions (FAs) and is comprised of five loosely packed, antiparallel α-helix bundle domains. Four of these helix bundles are organized in a head (VH) domain that is connected to a five-helix bundle vinculin tail (Vt) domain by a disordered proline-rich region ([@bib5]), which functions as a hinge for the molecule. The inactive closed state of vinculin is characterized by extensive intramolecular hydrophobic head--tail interactions of its N-terminal helix bundle domain (Vh1) with Vt, and physiological triggers such as talin that activate vinculin disrupt these interactions, and allow the tail domain of the open conformer to bind to other ligands, including PIP~2~ (but not other lipids; [@bib61]; [@bib44]) and F-actin ([@bib28]; [@bib45]). PIP~2~ levels are locally elevated at cell adhesion sites and PIP~2~ has been proposed to prevent F-actin binding ([@bib54]), to regulate FA turnover ([@bib7]; [@bib52]), and to activate vinculin ([@bib2]). This latter model was challenged by mutational analyses, which revealed that vinculin mutants that cannot bind to PIP~2~ still localize to FAs ([@bib7]) and by the structure of full-length vinculin, which established that the basic patch thought to bind PIP~2~ is occluded by an extended coil of Vt that lies over the face of the C terminus and α-helix H1 ([@bib3]; [@bib5]). More convincingly, mechanical tension emanating from integrin receptors has been shown to activate vinculin at FAs via its effects on the structure of integrin-bound talin, which releases amphipathic vinculin binding sites (VBSs) from their buried locales in helix bundle domains of the central rod domain of talin to then bind to Vh1 and displace Vt from a distance ([@bib16]; [@bib70]; [@bib20]).

Activated vinculin is found as higher-order oligomers in cells ([@bib41]; [@bib42]; [@bib22]; [@bib29]; [@bib66]), and this is mediated by Vt--Vt interactions ([@bib2]; [@bib43]; [@bib1]). Indeed, Vt can dimerize at high concentrations ([@bib2]; [@bib43]), even in the presence of F-actin ([@bib22]; [@bib2]; [@bib26]; [@bib58]). However, oligomerization is markedly augmented by PIP~2~, which drives the formation of dimers, trimers, and higher-order oligomers ([@bib23]; [@bib2]; [@bib66]; [@bib44]). Although cross-linking and limited proteolysis analyses have suggested that self-association, PIP~2~-induced dimerization, and F-actin--induced dimerization of vinculin are distinct ([@bib2]; [@bib29]), extensive mutagenesis studies ([@bib61]; [@bib30]; [@bib2]; [@bib29]; [@bib52]; [@bib11], [@bib12]; [@bib44]; [@bib65]) have failed to reveal the PIP~2~ binding sites.

Here we report the oligomeric structure of human vinculin in complex with PIP~2~ at a 3.2-Å resolution. This structure and analyses of bona fide PIP~2~-binding defective mutants establish essential functions for this signaling lipid in driving protein oligomerization, and in modulating interactions with the actin cytoskeleton and RNA-binding protein raver1. Importantly, this structure lays the foundation for understanding the roles of signaling lipids in other cytoskeletal proteins.

Results
=======

Architecture of PIP~2~-bound vinculin oligomers
-----------------------------------------------

Full-length vinculin is monomeric in solution, and, once activated, vinculin oligomerizes at sites of FAs ([@bib23]). Binding of the inositol head group and the hydrophobic acyl chain poses difficulties in generating PIP~2~-bound protein crystals. Indeed, the Vt--PIP~2~ complex crystal structure reported here represents only the third nonmembrane protein--PIP~2~ structure (out of five in total; [@bib51]; [@bib21]; [@bib32]; [@bib46]). Further, the propensity of Vt to self-associate posed difficulties. We initially obtained ∼5 Å diffraction, which could only be improved to 3.2 Å (space group *P*3~2~12; *a* = *b* = 102.58 Å, *c* = 190.77 Å) by using an R1060A mutation in the presence of a shorter chain (C8) derivative of PIP~2~ ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). The Arg-1060 side chain is solvent exposed and resides \>13 Å from the PIP~2~ binding site ([Fig. 1 A](#fig1){ref-type="fig"}), and this alanine substitution has no effect on the conformation of vinculin nor upon the data and conclusions presented herein. Consistent with proteolysis studies ([@bib2]), in the Vt--PIP~2~ structure, one PIP~2~ ligand is sandwiched between two Vt molecules by interacting with the loop connecting the first α-helices, H1 and H2 ([Fig. 1 B](#fig1){ref-type="fig"}). Dimer formation is mediated by the interactions of the 4′ and 5′ phosphates with Vt (molecule "I") Lys-915 and Lys-1061, and with Ser-913 through a water-mediated interaction. Lys-915 is also within hydrogen bonding distance to the carbonyl of the inositol. PIP~2~ bridges one Vt (I) molecule to another Vt (II), where the carbonyl of the glycerol backbone and of the inositol reside within hydrogen bonding distance of Lys-915 and where there is a water-mediated interaction of the carbonyl of the glycerol backbone with Ser-913 ([Fig. 1, C--E](#fig1){ref-type="fig"}). Further, PIP~2~ directs trimer formation, where the sandwiched PIP~2~ interacts with α-helix H3 of a third Vt (III) molecule ([Fig. 1 F](#fig1){ref-type="fig"}) from an adjacent dimer via distinct interactions of Lys-944 and Arg-945 with the hydroxyl groups of the inositol ([Fig. 1, C--E](#fig1){ref-type="fig"}). Significantly, Lys-944 is strictly conserved across all 25 known species. The lipid acyl chains are mainly solvent exposed with limited hydrophobic interactions to the Lys-915 side chain. This architecture allows for vinculin to anchor in the lipid bilayer.

###### 

Vt--PIP~2~ x-ray data reduction statistics

  Statistics                                    Overall         Last shell
  --------------------------------------------- --------------- --------------
  Resolution                                    45.17--3.20 Å   3.37--3.20 Å
  Total measurements                            142,775         20,959
  No. of unique reflections                     19,218          2,744
  *R*~p.i.m~[a](#tblfn1){ref-type="table-fn"}   0.02            0.33
  CC~1/2~[b](#tblfn2){ref-type="table-fn"}      0.999           0.725
  CC\*[c](#tblfn3){ref-type="table-fn"}         1.0             0.914
  Average I/σ(I)                                22.1            2.4
  Completeness                                  0.997           1.0
  Redundancy                                    7.4             7.6

CC, correlation coefficient.

Precision-indicating merging *R* factor ([@bib63]; [@bib62]).

Pearson CC calculated between the average intensities of each random half of measurements of unique reflections ([@bib31]).

CC\* estimates the value of the true level of signal CC~true~ (the correlation of the averaged and thus less noisy data set with the noise-free true signal), based on a finite-size sample ([@bib31]).

![**PIP~2~ directs vinculin oligomerization by unfurling the N terminus of Vt.** (A) The R1060A mutation used for crystallization does not affect PIP~2~ (oxygen, phosphor, and carbon atoms are shown as red, orange, and white sticks, respectively) binding. Vt α-helices are colored sequentially across the color spectrum from red (H1) to blue (H5). PIP~2~ and residues 1,060 and 1,061 are depicted, and residues 1,060 and 1,061 and Vt α-helices H1--H5 are labeled. (B) PIP~2~ directed dimerization of the vinculin five-helix bundle tail domain (α-helices are colored sequentially across the color spectrum from red (H1) to blue (H5), monomers are labeled as I and II) by binding to the α1-α2 loops and the C terminus of Vt. (C--E) Close-up view of the PIP~2~-directed oligomerization of Vt (α-helices and bonds are colored sequentially across the color spectrum from red to blue). Residues Lys-944 and Arg-945 are contributed from a third (III) monomer within the trimer. (D and E) View of the second (D; shown in blue) and third (E; shown in green) PIP~2~ in the asymmetric unit in the same orientation as in C, which indicates the specificity. (F) The PIP~2~-directed Vt trimer. Vt α-helices are colored sequentially across the color spectrum from red to blue, PIP~2~ is shown as spheres, and the three Vt molecules are labeled I--III. (G) With the exception of the loop connecting the last α-helix H5 to its C-terminal extended coil, unbound Vt (shown in cyan) superposes onto PIP~2~-bound Vt with a root-mean-square deviation (RMSD) of \<0.5 Å for ∼970 atoms (depending on the monomer in the asymmetric unit). However, the PIP~2~ binding site coincides with the N-terminal extended coil (in particular residues 881--886, indicated by a red "N"), which is unfurled in the PIP~2~-bound structure.](JCB_201404128_Fig1){#fig1}

PIP~2~ binding alters vinculin structure
----------------------------------------

In the unbound structure, the N-terminal extended coil of Vt occupies the PIP~2~ binding site, and PIP~2~ binding unfurls this region ([Fig. 1 G](#fig1){ref-type="fig"}). In addition to the side chain movements accompanied by PIP~2~ binding, lipid-directed dimerization replaces the His-906 stacking with Phe-885 with the more stable cation--Π interaction of the bulkier Trp-1064 indole ring stacking with His-906, which orders this otherwise disordered region in all known vinculin structures ([@bib2], [@bib3]; [@bib5]; [@bib24]; [@bib34]; [@bib50]). In the apo structure, the N-terminal extended coil, in particular Pro-886, is located where Trp-1064 lies in the PIP~2~-bound structure. In contrast, in the closed conformation of full-length vinculin, Phe-885 stacks against His-906, and Asp-882 and Glu-880 engage in electrostatic interactions with Lys-924 or with Lys-924 and Lys-1061, respectively.

PIP~2~ binding to vinculin differs from other canonical PIP~2~ binding motifs such as the KK(X)~n~K/RK motif in pleckstrin homology (PH) domain containing proteins, epsin N-terminal homology (ENTH) domains, band 4.1 protein, ezrin, radixin and moesin (FERM) domains, Bin-Amphiphysin-Rvs167 (BAR) domain containing proteins, or myristoylated alanine-rich C-kinase substrate (MARCKS), where a cluster of positively charged residues are arranged next to each other to electrostatically sequester the local PIP~2~ concentrations ([@bib40]). However, in the case of our vinculin--PIP~2~ interface, there is no canonical sequence motif.

To validate the PIP~2~-bound structure, we performed vesicle pull-down assays of wild-type and mutant forms of vinculin-bearing mutations in key lysine and arginine residues that, according to their structure, mediate interactions with PIP~2~. While Vt truncations destabilize the Vt five-helix bundle ([@bib44]), our Vt point mutations do not interfere with binding of Vt to the VH domain ([Fig. 2 A](#fig2){ref-type="fig"} and [Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201404128/DC1){#supp1}) or to F-actin ([Fig. 4 A](#fig4){ref-type="fig"} and [Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201404128/DC1){#supp2}). These studies revealed an almost complete loss of lipid binding for the K1061Q mutant ([Fig. 2 B](#fig2){ref-type="fig"} and Fig. S1, B and C**)**. Thus, Lys-1061 plays key roles in vinculin binding to the lipid bilayer.

![**Pull-down assay to analyze the lipid-binding capacity of vinculin.** (A) The interaction of wild-type and mutant Vt with VH was analyzed by electrophoretic mobility shift assays on a native gel, incubating the respective Vt proteins with VH. All proteins formed a Vt--VH complex. Data shown are representative of three independent experiments. (B) Unilamellar vesicles of the phospholipids PC and 15% PIP~2~ were incubated with wild-type and mutant Vt (top: K915Q, K924Q, K944Q/R945Q, K970Q, R1057Q, and K1061Q; bottom: K915Q/K1061Q, K944Q/R945Q/K1061Q, and K915Q/K944Q/R945Q) and sedimented. Supernatant (S) and pellet (P) fractions were detected on Coomassie-stained SDS-PAGE gel. Inactive and talin-VBS3 (residues 1,945--1,970) activated full-length (FL) vinculin were run as the nonbinding and binding controls, respectively. Densitometric values averaged over three experiments together with their standard deviations are shown above or below the respective experiment (gray bars, supernatant; white bars, pellet) and are as follows. (top) Wild type, 49.9% unbound in the supernatant with a standard deviation of 0.19; K915Q, 71.2%, 2.5; K924Q, 64.5%, 3.03; K944Q/R945Q, 89.3%, 1.35; K970Q, 48.7%, 2.5; R1057Q, 60%, 2.1; R1061Q, 96%, 0.72; (bottom left) wild type, 50%, 0.4; K915Q/K1061Q, 95.9%, 0.9; K944Q/R945Q/K1061Q, 97%, 0.9; K915Q/K944Q/R945Q, 93.7%, 1.1; (bottom right) full-length vinculin with VBS, 84.6%, 1.3; full-length vinculin alone, 99%, 0.1. The white line in one panel indicates the removal of unrelated lanes for presentation purposes. The corresponding full-length gels are shown in [Fig. S1 B](http://www.jcb.org/cgi/content/full/jcb.201404128/DC1){#supp3}. Error bars indicate SD. (C) Previously identified residues on α-helix H3 reside near the PIP~2~-induced Vt--Vt interface. Shown is a close-up view of the PIP~2~-directed Vt (α-helices are colored sequentially across the color spectrum from red \[H1\] to blue \[H5\]) interface between subunits II and III. Residues Lys-952, Lys-956, and Arg-963, which were previously thought to bind to PIP~2~, reside near or at the Vt--Vt interface, which might explain the decreased binding of the potentially oligomer-defective mutant (K952Q, K956Q, and R963Q) Vt compared with wild-type Vt.](JCB_201404128_Fig2){#fig2}

In the context of the full-length vinculin structure, the PIP~2~ binding site is on the surface of the protein and is distinct from the head--tail interface. However, PIP~2~ binding to full-length vinculin is impaired ([Fig. 2 B](#fig2){ref-type="fig"} and Fig. S1 D) because the N-terminal extended coil occludes the binding site ([Fig. 3 A](#fig3){ref-type="fig"}). Indeed, truncation of residues 879--897 increases Vt binding to PIP~2~ approximately twofold ([@bib44]). In contrast, talin VBS-activated full-length vinculin is fully permissive for lipid binding ([Fig. 2 B](#fig2){ref-type="fig"} and Fig. S1 D). Our structural and biochemical data fully support a PIP~2~-directed full-length vinculin dimer as a building block for higher-order vinculin oligomers ([Fig. 3 B](#fig3){ref-type="fig"}).

![**PIP~2~ binding in the context of full-length vinculin.** (A) The PIP~2~ binding site is distinct from the head--tail interface. Superposition of Vt--PIP~2~ onto full-length vinculin highlights the steric hindrance of the Vt N-terminal extended coil in the full-length vinculin--PIP~2~ model (Vt α-helices are colored sequentially across the color spectrum from red \[H1\] to blue \[H5\]; Vh1, residues 1--258 are shown in dark gray; the remainder of VH, residues 259--843, is shown in light gray; PIP~2~ is shown as spheres). The disordered regions (residues 844--876 and 1,063--1,066) are indicated. PIP~2~ binding orders the C terminus, and the Vt--PIP~2~ structure is the only vinculin structure that has interpretable electron density for the last residues. (B) PIP~2~-directed oligomerization of full-length vinculin. Once vinculin is activated and its head and tail domain severed, PIP~2~ directs vinculin oligomerization by binding to three Vt molecules. For clarity, only one PIP~2~ molecule, interacting with Lys-944 and Arg-945 of vinculin (III), is shown, whereas the PIP~2~ molecules bound to Lys-944 and Arg-945 of vinculin (I) and (II), which form a higher-order oligomer, are not shown. Vt α-helices are colored sequentially across the colorspectrum from red (H1) to blue (H5), VH are shown in gray, and PIP~2~ is represented with spheres.](JCB_201404128_Fig3){#fig3}

The PIP~2~ and F-actin binding sites of vinculin are distinct
-------------------------------------------------------------

Activated vinculin binds directly to F-actin ([@bib27]; [@bib64]) and caps actin filaments to promote their polymerization ([@bib47]; [@bib33]). This is thought to play critical roles at the leading edge of migrating cells ([@bib13]). Both PIP~2~ and F-actin bind to the Vt domain, and PIP~2~ binding has been reported to inhibit F-actin binding ([@bib54]). We therefore tested the structure-based PIP~2~-binding--deficient mutants of vinculin for their ability to interact with F-actin. Notably, all PIP~2~-binding deficient mutants cosedimented with F-actin ([Fig. 4 A](#fig4){ref-type="fig"} and Fig. S2), and also bundled F-actin, as seen with wild-type vinculin ([Fig. 4 B](#fig4){ref-type="fig"} and [Fig. S3](http://www.jcb.org/cgi/content/full/jcb.201404128/DC1){#supp6}). Although the Vt F-actin binding sites have been hotly debated ([@bib53]; [@bib26]; [@bib56], [@bib57]), the recently characterized I997A and V1001A mutants do show decreased binding to F-actin ([@bib55]). These residues reside \>12 Å from the PIP~2~-binding site ([Fig. 4 C](#fig4){ref-type="fig"}). Thus, the PIP~2~ and F-actin binding sites of vinculin are distinct.

![**The lipid-binding--deficient vinculin mutants bind and bundle F-actin.** (A) Wild-type and mutant Vt (top: K915Q, K944Q/R945Q "944," K1061Q, K915Q/K944Q/R945Q "915 944," K915Q/K1061Q; K944Q/R945Q/K1061Q "944 1061"; bottom: K924Q, K970Q, and R1057Q) were cosedimented with F-actin and analyzed on Coomassie-stained SDS-PAGE. Full-length (FL) vinculin was run as the nonbinding control. S, supernatant; P, pellet. The white lines indicate the removal of unrelated lanes for presentation purposes. Data shown are representative of three independent experiments. The corresponding full-length gels are shown in [Fig. S2 (A--C)](http://www.jcb.org/cgi/content/full/jcb.201404128/DC1){#supp4}. (B) Confocal images of TRITC-phalloidin--labeled F-actin in the absence or presence of wild-type or mutant (K1061Q or K915Q/K944Q/R945Q/K1061Q) Vt domain. Data shown are representative of three independent experiments. Larger micrographs corresponding to these panels are shown in [Fig. S3](http://www.jcb.org/cgi/content/full/jcb.201404128/DC1){#supp5}. Bars, 20 µm. (C) Model based on the superposition (not depicted) of the cryo-EM Vt--F-actin structure ([@bib57]; F-actin subunits are shown in gray or black) onto the PIP~2~-bound Vt dimer (α-helices H1--H5 are colored sequentially across the color spectrum from red \[H1\] to blue \[H5\]; PIP~2~ are represented as spheres), which suggests that vinculin has distinct F-actin and lipid binding sites. Residues Ile-997 and Val-1001 residing on α-helices H3 (green) that exhibit a significant decreased affinity for F-actin ([@bib57]) are also shown as spheres.](JCB_201404128R_Fig4){#fig4}

The raver1--vinculin complex does not bind to PIP~2~
----------------------------------------------------

The RNA-binding protein raver1 simultaneously binds to *vinculin* mRNA and the Vt domain of activated vinculin, and this interaction has thus been postulated to control local production of vinculin to facilitate FA assembly ([@bib34], [@bib35]; [@bib38]; [@bib50]). Interestingly, Arg-945 that binds PIP~2~ is also involved in electrostatic interactions with the raver1 residue Glu-120 ([Fig. 5, A and B](#fig5){ref-type="fig"}). To test if the lipid-binding--deficient K944Q/R945Q mutant binds raver1 and if the raver1--Vt complex binds PIP~2~, we ran the wild-type and mutant Vt--raver1 complexes on a size exclusion chromatography column ([Fig. 5, C and D](#fig5){ref-type="fig"}) and performed lipid cosedimentation assays ([Fig. 5 E](#fig5){ref-type="fig"}). Interestingly, although the K944Q/R945Q vinculin mutant still bound to raver1, the complex eluted earlier than the wild-type Vt--raver1 complex. Further, the crystal structures suggested that the raver1 and PIP~2~-binding sites are overlapping ([Fig. 5, A and B](#fig5){ref-type="fig"}), and indeed the Vt--raver1 complex did not bind to PIP~2~ ([Fig. 5 E](#fig5){ref-type="fig"}). Thus, although Vt--raver1 can form a ternary complex with F-actin ([@bib34]), the Vt--raver1 complex does not bind to the membrane.

![**Raver1 and PIP~2~ binding to vinculin is mutually exclusive.** (A) Superposition of the Vt--raver1 structure onto the Vt--PIP~2~ structure. Vt α-helices are colored sequentially across the color spectrum from red (H1) to blue (H5), monomers are labeled I--III, and raver1 is shown in gray. Superposition of lipid-bound Vt (I) onto the raver1-bound Vt shows overlapping binding of Vt (III) and raver1. (B) Close-up view of some interface residues. In its raver1-bound state, vinculin residue Arg-945 engages in interactions with raver1 residues Glu-120 and Arg-117, whereas in its lipid-bound state, Arg-945 points toward PIP~2~. (C) Size exclusion chromatogram (SEC) of Vt--raver1 (blue line; peak \#4 eluting at 14.56 ml; apparent mol wt = 54.6 kD; polypeptide chain mol wt = 51.2 kD), Vt-K944Q/R945Q/raver1 (black line; peak \#5, 15 ml; apparent mol wt = 45 kD; polypeptide chain mol wt = 51.2 kD), raver1 (dotted line; peak \#3, 15.77 ml; apparent mol wt = 32.19 kD; polypeptide chain mol wt = 31.5 kD), and Vt (gray line; peak \#1, 17.2 ml; apparent mol wt =17.22 kD; polypeptide chain mol wt = 19.7 kD). (D) SDS-PAGE of peak fractions from the SEC shown in the previous panel. The lane numbers correspond to the peak numbering in the previous panel. (E) Lipid cosedimentation assay of the Vt--raver1 complex. The Vt--raver1 complex does not cosediment with PIP~2~ and remains in the soluble (S) fraction. P, pellet.](JCB_201404128_Fig5){#fig5}

The vinculin--PIP~2~ interaction affects the actin cytoskeleton, cell migration, and FA turnover
------------------------------------------------------------------------------------------------

PIP~2~ binding to vinculin has been proposed to play roles in the turnover of FAs ([@bib7]; [@bib52]). *Vinculin*-null mouse embryonic fibroblasts (MEFs) have few and very unstable FAs, and those present fail to form links to the actin cytoskeleton, which is disorganized in these cells ([@bib15]). Confocal immunofluorescence studies demonstrated that exogenously expressed wild-type GFP-tagged vinculin colocalized with paxillin in FAs in *vinculin*-null MEFs ([Fig. S4](http://www.jcb.org/cgi/content/full/jcb.201404128/DC1){#supp7}) and led to reestablishment of a well-organized actin network ([Fig. 6](#fig6){ref-type="fig"}). In contrast, the expression of similar levels of GFP-vinculin--bearing mutations that block PIP~2~ binding resulted in colocalization with paxillin but did not rescue the chaotic actin network that is manifest in *vinculin*-null MEFs ([Fig. 6](#fig6){ref-type="fig"}).

![**PIP~2-~directed oligomerization of vinculin contributes to the stabilization of FAs.** *Vinculin^−/−^* MEFs engineered to express wild-type GFP-vinculin or mutant GFP-vinculin fusions (K944Q/R945Q and R1061Q) were analyzed by confocal laser-scanning microscopy. MEFs were grown on gelatin-coated coverslips, fixed after 24 h, and stained with TRITC-phalloidin to visualize the actin cytoskeleton. Representative images, which define the localization of GFP-vinculin (green) at FAs decorating F-actin (red), along with the merged channels, are shown. Also shown are nuclei stained with DAPI. Data shown are representative of three independent experiments. Bars, 100 µm.](JCB_201404128_Fig6){#fig6}

Although *vinculin^−/−^* MEFs can assemble a modicum of FAs, they have defects in cell spreading, and their migration is chaotic and rapid. In wound healing assays, these cells close a wound faster than paired *vinculin*^+/+^ cells ([@bib67]; [@bib52]). To assess the effects of the vinculin--lipid interaction on FAs in these cells, we performed scratch-wound healing assays ([Fig. 7](#fig7){ref-type="fig"}). Expression of wild-type vinculin suppressed the enhanced but chaotic wound closure typical of *vinculin*-null cells and led to a tighter closure of the wound. In contrast, forced expression of lipid-binding--deficient vinculin mutants led to marked suppression of wound closure, which indicates that the lipid-binding--deficient mutants of vinculin have defects in cell migration. Collectively, these findings were consistent with the notion that the PIP~2~--vinculin interaction might play roles in FA turnover.

![**MEFs expressing the PIP~2~-binding--deficient mutant of vinculin are impaired in wound closure.** *Vinculin*-null cells (left) that were engineered to express comparable levels of wild-type vinculin (center left) or K944Q/R945Q or K1061Q mutant vinculin (center right and right) were plated onto fibronectin-coated 12-well plates. Monolayers were then wounded, and the extent of cell migration into the wound was recorded at 0, 4, 8, and 12 h. *Vinculin*-null cells migrate in a rapid yet chaotic fashion, whereas wound closure in these cells expressing wild-type vinculin is an ordered process. *Vinculin*-null cells expressing K944Q/R945Q or K1061Q mutant vinculin had reduced migration and wound closure versus cells expressing wild-type vinculin. Data shown are representative of three independent experiments. Bars, 20 µm.](JCB_201404128_Fig7){#fig7}

Direct measurement of wild-type GFP-vinculin turnover in FAs by FRAP revealed that the entire population within the FA is turning over with a half-time of ∼20 s ([Fig. 8](#fig8){ref-type="fig"}), a value in the range of what was previously reported ([@bib7]). However, FRAP analysis of the lipid-binding--deficient vinculin mutants revealed that a large fraction (∼45% for the K1061Q mutant and \>90% for the K944Q/R945Q mutant) of the GFP-vinculin within these FAs is immobile or much more tightly bound in that it did not recover within the time frame that results in complete recovery for the wild-type protein ([Fig. 8](#fig8){ref-type="fig"}). Notably, the mobile fraction of the K1061Q mutant vinculin in FAs displayed recovery kinetics that were significantly faster than wild-type vinculin, which is indicative of a much lower binding affinity. The immobile or tightly bound fraction may represent static nonfunctional interactions within the FA, which is consistent with the inability of these cells to organize the actin network and suggest that the dynamic turnover of vinculin is compromised in the PIP~2~-binding--deficient mutants. We conclude that the PIP~2~--vinculin interaction plays important roles in the stabilization and dynamic turnover of FAs.

![**FRAP analyses of wild-type and mutant GFP-vinculin in FAs.** (A) Representative images of FRAP recovery. The arrows indicate the bleached FA. (B) FRAP recovery curves for the mean of at least eight independent measurements for each cell line are displayed. The t~50~ values for wild-type (19 s) and the K1061Q mutant (7 s) were determined by fitting the curves to a single exponential. A t~50~ value for the K944Q/R945Q mutant could not be determined due to the absence of significant recovery. The immobile fraction is represented by the difference between the normalized plateau value and the prebleach fluorescence, and was estimated to be \<5% for the wild-type cells, ∼45% for the K1061Q mutant, and \>90% for the K944Q/R945Q mutant. Error bars indicate SD.](JCB_201404128_Fig8){#fig8}

Discussion
==========

The binding of integrins to extracellular matrix components at FAs triggers mechanical force on associated talin molecules, which opens up helix bundles and exposes VBSs that then bind to and activate vinculin to stabilize nascent cell--matrix adhesions via its associations with F-actin ([@bib16]; [@bib18]; [@bib69]). The role of PIP~2~ binding in the regulation and function of vinculin has been hotly debated ([@bib19]; [@bib3]; [@bib24]; [@bib4]; [@bib8]). Our studies establish that the PIP~2~ binding site is occluded in full-length vinculin and they demonstrate that PIP~2~ binding is necessary to mediate interactions of vinculin with F-actin at FAs. Our studies also suggest that F-actin and PIP~2~ binding to vinculin is mutually permissive, as they clearly have distinct binding sites on vinculin. These findings are consistent with a model whereby PIP~2~ binding triggers the formation of higher-order oligomers of activated vinculin that are competent to make multiple contacts with F-actin that would stabilize FAs, particularly because the cryo-EM structure suggests that one molecule of vinculin can be sandwiched between two molecules of F-actin ([@bib25]).

The crystal structure reveals that PIP~2~ principally affects vinculin function by directing vinculin oligomerization. Specifically, PIP~2~ directs the formation of vinculin dimers by releasing a flexible N-terminal extended coil present in the Vt five-helix bundle, and by bridging the flexible C terminus of one Vt molecule with α-helix H1 of a second Vt molecule, thereby restraining the conformation of the C terminus and stabilizing the dimer. Further, this signaling lipid directs vinculin trimerization via interactions with two lysine residues on α-helix H3 that are at the head--tail interface in inactive vinculin. Other basic residues on H3 have been proposed to direct the vinculin--lipid interaction ([@bib7]), and examination of our crystal structure reveals that these residues are rather near the lipid-induced Vt--Vt interface ([Fig. 2 C](#fig2){ref-type="fig"}). Thus, mutating these residues might have prevented this Vt--Vt association by hindering vinculin oligomerization, and this might explain the decreased lipid binding. Finally, the crystal structures explain how higher-order vinculin oligomers can occur after PIP~2~ binding, a response that allows amplification of the interactions of vinculin with talin, and with F-actin, at FAs.

The RNA-binding protein raver1 has been proposed to regulate the local assembly of nascent FAs by binding to mRNAs encoding components of FAs in order to allow their localized translation at these sites. Specifically, raver1 binds to both Vt and *vinculin* mRNA, and the ternary Vt--raver1--vinculin mRNA complex is permissive for binding to F-actin. In contrast, the raver1 and PIP~2~ binding sites on vinculin overlap, and our studies have shown that the vinculin--raver1 complex does not bind to PIP~2~. This is consistent with a model where raver1 binding to vinculin is spatiotemporally regulated and where the F-actin--vinculin--raver1 complex bound to *vinculin* mRNA is not attached to the plasma membrane.

While the F-actin binding sites on vinculin are also controversial ([@bib53]; [@bib26]; [@bib56]; [@bib57]), the recently identified I997A and V1001A mutants showed decreased F-actin binding. Notably, the crystal structure of the vinculin--PIP~2~ complex establishes that Ile-997 and Val-1001 are not involved in the PIP~2~ binding sites of vinculin. Further, PIP~2~-binding--deficient mutants of vinculin still bind F-actin in vitro; thus, binding of PIP~2~ and F-actin to vinculin seems mutually permissive. Finally, these findings suggest similar mechanisms of action for this signaling lipid in controlling the structure and functions of other lipid-and-actin-binding cytoskeletal proteins, where we propose that PIP~2~ may play roles in oligomerization of these targets that are also permissive for binding to F-actin.

We present three observations suggesting that binding of PIP~2~ by vinculin is an integral component of proper FA function. The exogenous expression of wild-type GFP vinculin, but not lipid-binding--deficient mutants, in *vinculin*-null MEFs resulted in the reestablishment of a well-organized actin network. *Vinculin*-null MEFs expressing lipid-binding--deficient GFP-vinculin displayed a severe impairment of cell migration in wound closure assays. Finally, direct measurement of vinculin recruitment to FAs by photobleaching revealed that wild-type vinculin displays dynamic turnover, with the entire population being replaced within the time frame of minutes. However, we find that a large portion of the PIP~2~-binding--deficient mutant vinculin is immobile or tightly bound, possibly due to static nonfunctional interactions within the FAs. Thus, although lipid-binding--deficient vinculin does localize to FAs, the observations noted here would suggest that the interactions within these FAs are distinct from those of wild-type vinculin and that these differences compromise FA function, which is consistent with the inability of these cells to organize the actin network or to close a wound. Previously, a modified FRAP procedure was used to show that a PIP~2~-binding--defective vinculin mutant was recruited to FAs, but disassembly was depressed ([@bib7]). In a subsequent study, interference reflection microscopy was used to demonstrate that FAs in cells expressing a lipid-binding--deficient mutant displayed reduced turnover and translocation ([@bib52]). The results from these studies are in agreement with our conclusion that the PIP~2~--vinculin interaction is critical for the dynamic turnover of FAs and that this interaction is compromised in the PIP~2~-binding--deficient mutants. Our vinculin--PIP~2~ structure and functional data will aid future studies to understand how lipid-binding--deficient vinculin mutants affect the actomyosin contractile forces as these mutants significantly disturb the F-actin network.

Materials and methods
=====================

Protein preparation
-------------------

Full-length human vinculin cDNA (residues 1--1,066) was cloned into a pET3 expression vector, and a noncleavable His~8~ tag was added downstream to the vinculin coding sequence. Modified pET-3 vector was used for cloning the head domain of vinculin (VH; residues 1--843) with a PreScission protease cleavable C-terminal octa-histidine tag. This expression vector contains a T7 promoter and contains an ampicillin resistance gene. For vinculin and VH purification, cell pellets were resuspended in 20 mM Tris-HCl, pH 8, and 150 mM NaCl, lysed by sonication, and clarified by ultracentrifugation (100,000 *g* for 45 min). The cell lysate was loaded onto a nickel affinity column (GE Healthcare), which was equilibrated with 20 mM Tris-HCl, pH 8, and 150 mM NaCl, and eluted the proteins using 0.5 M imidazole gradient. Further, proteins were purified by gel filtration using a Superdex 200 column (GE Healthcare), then equilibrated in 20 mM Tris-HCl, pH 8.0, and 150 mM NaCl. Purified vinculin protein was further dialyzed against 10 mM Tris-HCl, pH 8, 0.1 mM EDTA, and 3 mM DTT buffer. Vinculin and VH were concentrated to 29 mg/ml and 10 mg/ml, respectively.

Site-directed mutants of vinculin (K915Q, K924Q, K944Q/R945Q, K970Q, R1057Q, R1060A, K1061Q, K915Q/K944Q/R945Q, K915Q/K1061Q, and K944Q/R945Q/K1061Q) were generated from the tail domain (Vt) of wild-type vinculin using Agilent Technology's QuikChange site-directed mutagenesis kit. These mutants were cloned into the pGEX-6P1 expression vector (EMD Millipore) to obtain N-terminal GST-tagged proteins. All Vt constructs were cloned into a pGEX-6P1 expression vector (GE Healthcare). The basic features of these plasmids are a tac promoter and lac operator upstream of the coding sequence of GST followed by a PreScission cleavage site (LEVLFQGP). Vt and its mutant proteins were cloned between BamHI and XhoI restriction enzyme sites, which are downstream to the PreScission cleavage site and GST tag. The coding sequence is terminated by a stop codon. This expression vector contains an ampicillin resistance gene. All mutations were confirmed by sequencing. For GST-Vt and the Vt mutant protein purification, the cell pellets were resuspended in 20 mM Tris-HCl, pH 8, and 400 mM NaCl, lysed by sonication, and clarified by ultracentrifugation (100,000 *g* for 45 min). Subsequently, the supernatant was applied onto a GSTrap FF column, and, after extensive washing with the buffer (20 mM Tris-HCl, pH 8, and 400 mM NaCl), the bound GST-Vt was eluted with 20 mM of reduced glutathione, pH 8. GST affinity tags were removed by overnight cleavage with PreScission protease at 4°C and dialyzed into 20 mM Tris, pH 8, 400 mM NaCl, 1 mM DTT, and 0.1 mM EDTA. All proteins were further purified by gel filtration using a 26/60 Superdex 75 column (GE Healthcare) that was preequilibrated with 20 mM Tris-HCl, pH 8, 400 mM NaCl, 1 mM DTT, and 0.1 mM EDTA. Peak fractions were collected and concentrated to 10 mg/ml.

VH and full-length vinculin were purified as described previously ([@bib49]) and dialyzed against 20 mM Tris, pH 8, 10 mM DTT, 1 mM EDTA, and 1 mM EGTA, and concentrated to ∼29 mg/ml. Talin-VBS3 (residues 1,945--1,970) was synthesized.

The RRM1-3 (residues 39--321) domains of human raver1 were cloned into the pET-28a vector (EMD Millipore) to produce N-terminal hexahistidine-tagged proteins. This expression vector has a T7 promoter and six-histidine residue coding sequence upstream of the RRM1-3 (residues 39--321) domain coding sequence. This bacterial expression vector contains a kanamycin resistance gene. RRM1-3 was expressed in *Escherichia coli* strain BL21-DE3 (Invitrogen). Bacteria were grown at 37°C in Luria-Bertani medium containing 20 µg/ml kanamycin. Bacterial cultures were induced at OD~600~ = 0.8 by adding isopropyl-[d]{.smallcaps}-thiogalactopyranoside to 0.5 mM and incubating at 20°C, and cells were harvested after 24 h. The cell pellet was resuspended in 20 mM Tris-HCl, pH 8, and 150 mM NaCl, lysed by sonication, and clarified by ultracentrifugation (100,000 *g* for 45 min). The cell lysate was loaded onto a HisTrap chelating nickel affinity column (GE Healthcare), which was equilibrated with 20 mM Tris-HCl, pH 8, and 150 mM NaCl, and we eluted the proteins using an imidazole gradient. Further, it was purified by gel filtration using a Superdex 75 column (GE Healthcare) equilibrated in 20 mM Tris-HCl, pH 8.0, and 150 mM NaCl. Protein fractions were collected and concentrated to 15 mg/ml.

Vt--PIP~2~ crystallization
--------------------------

Human Vt (residues 891--1,066) was incubated with 20 µM PIP~2~diC~8~ (Avanti Polar Lipids) on ice for 30 min. Excess precipitate was removed by centrifugation (15,800 *g* for 25 min at 4°C). We screened ∼1,000 commercially available crystallization conditions and obtained a crystallization hit from the PEG/Ion kit of Hampton Research. Crystals were grown within 2 d by hanging drop vapor diffusion from 50 mM Hepes, pH 7, 12% (wt/vol) PEG 3350, and 2% (wt/vol) Tryptone, at 20°C. They diffracted x-rays at various beam lines (11-1 at Stanford Synchrotron Radiation Laboratory \[SSRL\], or 22ID and 22BM at the Advanced Photon Source of the Argonne National Laboratory \[APS/ANL\]) to ∼5-Å Bragg spacings. All crystallization strategies and truncations failed to improve the diffraction, but ultimately crystals of the PIP~2~-bound R1060A complex diffracted to 3-Å Bragg spacings. The mother liquor was supplemented with 5% increments of glycerol to 25% and transferred and stored in liquid nitrogen at 100 K.

X-ray data collection and processing
------------------------------------

X-ray diffraction data were collected at the Advanced Photon Source 22-ID beam line (wavelength of 1 Å) and integrated and scaled using XDS and SCALA as implemented in autoPROC ([@bib60]). Data reduction statistics are provided in [Table 1](#tbl1){ref-type="table"}.

Structure determination and crystallographic refinement
-------------------------------------------------------

Phases were obtained by molecular replacement using the program MOLREP ([@bib59]), where the search model consisted of Vt from the Vh1--Vt complex (Protein Data Bank \[PDB\] accession no. [1RKE](1RKE)). A clear solution with six molecules in the asymmetric unit was obtained in space group *P*3~2~12, while for the enantiomer in *P*3~1~12, the *R* factor remained \>0.5 during refinement. An acceptable packing density, V~M~ ([@bib39]), was calculated at 2.45 Å^3^/Da, corresponding to a solvent content of ∼0.495.

Initial crystallographic refinement used a 3-Å cutoff, but best results were obtained using data up to 3.2-Å Bragg spacings. Maximum likelihood crystallographic refinement was performed using autoBUSTER ([@bib6]) by imposing target restraints using the high-resolution structures. The model was improved by local noncrystallographic symmetry restraints through local structure similarity restraints (LSSR; Smart, O.S., C. Brandl, P. Flensburg, W. Keller, C. Paciorek, C. Vonrhein, T. Womack, and G. Bricogne. 2008. Proceedings of the annual meeting of the American Crystallographic Association. Abstr. TP139). Iterative cycles of model building were performed using Coot ([@bib14]), and model bias was minimized by building into composite omit maps. Optimized ligand coordinates and ligand restraints were obtained from the Grade web server (grade.globalphasing.org). The electron density map was sharpened using Coot ([@bib14]) to ensure the directionality and identity of the α-helices. The quality of the final model was assessed using MolProbity ([@bib9]), which revealed no outliers with \>97% of the amino acid residues in the favored region of the Ramachandran plot. Crystallographic refinement statistics are provided in [Table 2](#tbl2){ref-type="table"}. The final model contains six Vt polypeptide chains and three PIP~2~ molecules. Residues 1,051--1,053 and 1,066 are missing due to weak electron density in this region.

###### 

Vt--PIP~2~ crystallographic refinement statistics

  Statistics                        Overall         Last shell
  --------------------------------- --------------- -------------
  Resolution                        45.17--3.20 Å   3.37--3.2 Å
  No. reflections (working set)     18,212          2,594
  No. of reflections (test set)     967             144
  *R*~work~/*R*~free~               0.206/0.253     0.235/0.277
  **No. atoms**                                     
  Protein                           8,090           
  PIP~2~                            141             
  Solvent                           75              
  ***B*-factors**                                   
  Protein                           147 Å^2^        
  PIP~2~                            235 Å^2^        
  Solvent                           92 Å^2^         
  **Root mean square deviations**                   
  Bond lengths                      0.010 Å         
  Bond angles                       1.11°           
  **Ramachandran plot**                             
  Favored                           96.95%          
  Allowed                           3.05%           
  Generously allowed                0%              
  Outliers                          0%              

Lipid cosedimentation assay
---------------------------

PIP~2~ binding to Vt mutants was assayed as described previously ([@bib44]). In brief, lipid vesicles of phosphatidylcholine (PC) and PIP~2~ were prepared by mixing together in chloroform to have a final composition of 85% PC and 15% PIP~2~. The lipid mixture was vacuum dried and resuspended in 20 mM Tris, pH 8, 400 mM NaCl, and 3 mM DTT. Unilamellar vesicles were then produced by sonication after incubating the vesicles at 37°C for 30 min. Samples containing 50 µg of total lipid in 10 µl suspension and 40 µM Vt (wild type or mutants) were incubated at 4°C for 1 h followed by centrifugation at 75,815 *g* for 30 min. The supernatant and pellet were separated, and the pellet was washed two times with buffer A and resuspended in 12.5 µl. The supernatant and pellet samples were analyzed by SDS-PAGE.

Native PAGE assay of Vt proteins binding to the VH domain
---------------------------------------------------------

About 5 µM VH (residues 1--840) was mixed with 2--3-fold excess of wild-type or mutant (K915Q, K944Q/R945Q, K1061Q, K915Q/K944Q/R945Q, K915Q/K1061Q, and K944Q/R945Q/K1061Q) Vt (residues 891--1,066) in 20 mM Tris, pH 8, 400 mM NaCl, and 1 mM DTT, then incubated at room temperature for 15 min. The samples were then analyzed on 10--15% gradient PHAST gel using native buffer strips, and the bands were visualized with Coomassie blue.

F-actin cosedimentation assay
-----------------------------

F-actin cosedimentation assays were performed as described previously ([@bib48]). In brief, 15 µM of F-actin was incubated with ∼8 µM Vt (or full-length vinculin) for 20 min at room temperature and the reaction mixture was pelleted at 125,000 *g* for 15 min at 20°C. The supernatant and pellet were further analyzed on SDS-PAGE and stained for protein bands with Coomassie blue.

F-actin bundling assay
----------------------

Fluorescence microscopic analyses of F-actin bundling by Vt domains were performed as described previously ([@bib49]), with slight modifications. In brief, G-actin (1 mg/ml) was prepolymerized in either Tris buffer (20 mM Tris-HCl, pH 8, 0.1 M KCl, 2 mM MgCl~2~, 1 mM ATP, and 0.4 mM CaCl~2~) or imidazole buffer (25 mM imidazole, pH 7.4, 0.1 M KCl, 2 mM MgCl~2~, and 1 mM ATP) for 1 h at 37°C. Reactions containing 2.7 µM prepolymerized F-actin with 2.3 µM of Vt or its PIP~2~-binding--deficient mutants were incubated for 1 h at room temperature. F-actin was subsequently labeled with an equimolar concentration (2.7 µM) of TRITC-phalloidin (Life Technologies) and incubated another half hour before mounting on poly-[l]{.smallcaps}-lysine--coated coverslips (Thermo Fisher Scientific). The confocal images of TRITC-phalloidin--labeled F-actin were captured at ambient temperature using a confocal laser scanning microscope (LSM 780; Karl Zeiss), equipped with a gallium arsenide phosphide (GaAsP) detector and Zen software, using a 63×/1.3 NA Apochromat multi-immersion objective lens using water as the imaging medium, and further adjusted for brightness/contrast with Fiji (ImageJ).

Size exclusion chromatography
-----------------------------

Purified raver1 (100 µM in 20 mM Tris, pH 8, and 150 mM NaCl) was incubated for 1 h at 4°C with wild-type or K944Q/R945Q mutant vinculin (20 mM Tris, pH 8, 400 mM NaCl, and 1 mM DTT) in a 1:2 molar ratio and run on an analytical S200 size exclusion chromatography column (equilibrated in 20 mM Tris, pH 8, 400 mM NaCl, and 3 mM DTT) with a flow rate of 0.5 ml/min. Vt and raver1 proteins, both at 100 µM, were also run separately. Fractions were analyzed on a 10--15% gradient PHAST gel with SDS-PAGE buffer strips.

Cell culture and immunofluorescence
-----------------------------------

*Vinculin*-deficient (*Vin^−/−^*) MEFs were provided by K. Burridge (University of North Carolina, Chapel Hill, NC). They were originally prepared by E. Adamson (Sanford-Burnham Medical Research Institute, La Jolla, CA): *vinculin*-null cells were isolated by targeting both alleles of the vinculin gene by homologous recombination in which exon 3 has been replaced by a neomycin resistance gene ([@bib67]). Vinculin-null cells were cultured in DMEM containing 4.5 g/liter glucose and 2 mM [l]{.smallcaps}-glutamine (Invitrogen) supplemented with 10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C and 5% CO~2~ in a humidified incubator, and passaged every 3--4 d. *Vin^−/−^* MEFs were transfected with the pcDNA4.1 plasmid DNA encoding full-length human wild-type or mutant vinculin as an N-terminal His~10~-EGFP fusion, or with the vector control, using Lipofectamine LTX plus reagent (Invitrogen) according to the manufacturer's protocol. All human vinculin constructs and PIP~2~-binding--deficient mutants used for cell biology studies were cloned into pcDNA4.1/TO/Myc-HisB vector (Life Technologies). The basic feature of these plasmids is a CMV promoter and two tandem tetracycline (2× TetO~2~) operator sequences upstream to the coding sequence of EGFP. EGFP coding sequence and a PreScission cleavage site (LEVLFQGP) downstream to it was introduced between the TET operator and the coding sequence of HV or the mutants. Further, a three-alanine linker was introduced in-between the PreScission cleavage site and the coding sequence of vinculin. The vinculin coding sequence is terminated by a stop codon (TGA) before the myc and hexahistidine tag. This mammalian expression vector contains Zeocin and ampicillin resistance genes. Stables were prepared using Zeocin. Cells were grown on six-well tissue culture treated plates for 48 h and were initially selected with medium containing 800 µg/ml Zeocin for 1--2 wk, then passaged every 3--4 d with fresh media containing 200 µg/ml Zeocin.

Preparation of cells for immunofluorescence detection for localization of vinculin in FAs was performed by plating the cells stably expressing vinculin (or mutants of vinculin) on a gelatin-coated coverslip. 24 h after plating, the cells were fixed for 10 min with 4% paraformaldehyde in PBS, pH 7.4, and permeabilized with 0.2% Triton X-100 in PBS. Blocking was performed with 1% BSA in PBS for 20 min and cells were stained with TRITC-phalloidin (5 µg/ml) for actin and with DAPI (0.1 µg/ml) for detecting nuclei. Additionally, cells (7 × 10^4^) were also seeded on 12-mm coverslips coated with 20 µg/ml fibronectin (Sigma-Aldrich) and incubated for 6 h. To visualize colocalization of vinculin and paxillin (another FA marker), cells were fixed and stained sequentially with mouse anti-paxillin antibody (BD) and Alexa Fluor 568 conjugated anti--mouse IgG (Life Technologies) followed by staining with DAPI for visualizing the nucleus. For imaging, the coverslips were mounted on a glass slide using Vectashield mounting medium (Vector Laboratories).

Fluorescence images were collected on confocal laser scanning microscope (LSM 780; Zeiss), controlled with Zen software, using a GaAsP detector. Cells were randomly selected and imaged at room temperature (23°C) using either a 63×/1.3 NA Apochromat multi-immersion objective lens using water as the imaging medium (for FA analysis) or a 20×/0.8 NA dry objective lens (for cell spreading). Excitations of the individual fluorophores in the stained cells were achieved using an argon laser (488 nm, for EGFP), a HeNe laser (633 nm for Alexa Fluor 633), and solid-state lasers (405 nm and 561 nm for DAPI and Alexa Fluor 568, respectively). Images were further processed using Fiji (ImageJ) for brightness/contrast adjustments for confocal images. Additionally, for quantification, the images were low-band-pass filtered, an auto-threshold function was applied, and manual masks were defined before using the "analyze particle" function for cell or area counting and FA analysis.

Immunoblotting
--------------

Cells showing stable and comparable levels of expression of vinculin or vinculin mutants were cultured to 70--80% confluency on gelatin-coated 10-cm Petri dishes in media supplemented with 200 µg/ml Zeocin, and were collected through trypsinization. The cells were washed twice with ice-cold PBS and resuspended in RIPA buffer (10 mM Tris-HCl, pH 8, 140 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, and protease inhibitor cocktail \[Roche\]) and briefly sonicated. The lysed samples were then separated by SDS-polyacrylamide gel, electroblotted on to Immobilon membrane (EMD Millipore) using a semidry transfer apparatus (Bio-Rad Laboratories), and incubated sequentially with anti-vinculin primary antibody and HRP-conjugated secondary antibody. The blots were then developed after treatment with chemiluminescence substrate (Thermo Fisher Scientific) according to the manufacturer's instructions.

Wound assays
------------

*Vinculin*-null MEFs and the cells stably expressing full-length wild-type or mutant vinculin were seeded at a density of 2 × 10^5^ cells/well on a 12-well plate, precoated with 20 mg/ml fibronectin. The cells were then incubated overnight at 37°C and 5% CO~2~ to achieve confluency the following day. The wound healing assay was initiated by scraping a line on the culture dish using a 200-µl pipette tip on the confluent cell monolayer. The culture dish was then gently washed with PBS to remove any cell debris and replenished with 1 ml of fresh media (DMEM with 10% bovine calf serum, 100 U/ml penicillin, and 100 µg/ml streptomycin). Cells were imaged on an EVOS FL cell imaging system (Life Technologies) equipped with a color charge-coupled device image acquisition system (ICX285AQ; Sony) through software built in to the onboard microprocessor. A 10×/0.25 dry objective lens was used for bright field imaging immediately afterwards in order to represent the zero time point, and the wound healing was monitored every 4 h, returning plates for incubation after every imaging session. All assays were repeated in triplicate. Each time, images were taken at six different points and the positions that were similar in wound distance were used for direct comparison.

FRAP assays
-----------

MEF cells were plated and observed in fibronectin-coated 35-mm^2^ glass-bottom culture dishes (MatTek Corporation). FRAP was performed on a laser scanning confocal microscope (TCS SP8; Leica) using the 488-nm line of an argon laser essentially as described previously ([@bib17]). All experiments were performed at 37°C, and imaging was performed with a Plan-Apochromat 63×/1.3 NA objective lens using the FRAP module of the LAS AF software (Leica). Bleaching of a single FA per cell was achieved using a single bleach scan of 273-ms duration at maximal laser power. Recovery was monitored at 500--575 nm and recorded for 90 s. Although movement of cells and/or FAs precluded longer measurements, a recovery plateau was reached within this time period for most of the imaged cells, except where noted. Identical imaging settings (5% laser intensity) were used for all pre- and post-bleach images. Scanning was bidirectional at the highest possible rate using a 4× zoom with a pinhole of 1 Airy unit. Image analysis was performed within the LAS AF software. Datasets were imported into Origin 6.0 and normalized recovery rates were fitted to a single exponential recovery model in OriginLab software using the equation *F(t)* = 1 − e^(−kx)^, where *F(t)* is the fluorescence at time *t*, *k* is the rate constant, and the *t~1/2~* of recovery was calculated from the rate constant *k* = ln 2/*t*~1/2~. All datasets consisted of at least eight cells per experiment.

Online supplemental material
----------------------------

Fig. S1 shows the full gels shown in [Fig. 2](#fig2){ref-type="fig"}. Fig. S2 shows the full gels shown in [Fig. 4](#fig4){ref-type="fig"}. Fig. S3 shows larger panels compared with those shown in [Fig. 4 B](#fig4){ref-type="fig"} as well as additional confocal images of TRITC-phalloidin--labeled F-actin in the presence of Tris-HCl, pH 8. Fig. S4 shows confocal immunofluorescence studies of exogenously expressed wild-type and lipid-binding--deficient mutant GFP-tagged vinculin colocalized with paxillin in FAs in *vinculin*-null MEFs, as well as immunoblots obtained with vinculin antibody after SDS-PAGE to analyze the expression of wild-type and mutant vinculin proteins in *vinculin*-null cells using the primary anti-vinculin antibody and a secondary HRP--conjugated anti--mouse IgG. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201404128/DC1>.
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